Groundbreaking findings on TET2 pathway open doors for targeted blood cancer treatments
Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2).
23 Oct 16:49 · News-Medical